Adma Biologics (ADMA) Change in Accured Expenses (2011 - 2025)

Adma Biologics has reported Change in Accured Expenses for 13 years, with the latest figure at $701000.0 in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses rose 338.44% year-over-year to $701000.0; the trailing twelve-month figure through Dec 2025 stood at $708000.0 (up 161.89% YoY), and the FY2025 full-year result was $708000.0, up 161.89% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $701000.0, up from -$1.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.1 million in Q2 2023, with the low at -$5.7 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged -$75500.0 across 5 years, with a median of -$215292.5 in 2022.
• Annual changes were most pronounced in 2021 — Change in Accured Expenses surged 12715.52% — and 2023, when it plunged 4046.14%.
• Adma Biologics' Change in Accured Expenses stood at -$5.3 million in 2021, then surged by 97.43% to -$136585.0 in 2022, then sank by 4046.14% to -$5.7 million in 2023, then soared by 94.81% to -$294000.0 in 2024, then jumped by 338.44% to $701000.0 in 2025.
• The last three Change in Accured Expenses figures came in at $701000.0 (Q4 2025), -$1.0 million (Q3 2025), and $3.4 million (Q2 2025), per Business Quant data.